Related Experiment Video
Updated: Aug 8, 2026

Isolation, Fixation, and Immunofluorescence Imaging of Mouse Adrenal Glands
Published on: October 2, 2018
Signal transduction in G0/G1-arrested mouse Y1 adrenocortical cells stimulated by ACTH and FGF2
A P Lepique1, F L Forti, M S Moraes
1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Brasil.
Abstract:
In G0/G1 cell cycle arrested mouse Y1 adrenocortical tumor cells ACTH39, a weak mitogen and strong anti-mitogenic agent, blocks FGF2 mitogenic activity at G1 phase, keeping untouched ERK-MAPK activation and c-Fos protein induction. Here we report two anti-mitogenic mechanisms initiated in ACTH receptors and mediated by cAMP/PKA: a) post-transcriptional down regulation of c-Myc protein; b) dephosphorylation of AKT/PKB. In Y-1 cells the activity of the Mad/Max/Myc network of transcription factors seems to be regulated by c-Myc levels. FGF2 induces c-myc gene and stabilizes c-Myc protein by a process dependent on ERK-MAPK (PD98059 sensitive), but not on PI3K (Wortmannin resistant). ACTH39, on the other hand, causes rapid decrease in c-Myc levels induced by FGF2 in wild type Y1 cells, but not in PKA-deficient Y1 clones. The ACTH inhibition of DNA synthesis stimulated by FGF2 is reversed by transient transfection and induction of the MycER chimera (fusion of c-Myc and estrogen-receptor), suggesting that c-Myc down regulation is an efficient anti-mitogenic mechanism activated by ACTH. Y1 cells display high constitutive levels of AKT/PKB, that is dependent on elevated Ras x GTP. FGF2 up regulates Ras x GTP, PI3K and AKT/PKB. ACTH antagonizes this mitogenic effect of FGF2, promoting rapid dephosphorylation of AKT/PKB.
Insights
Adrenocorticotropic hormone (ACTH) inhibits fibroblast growth factor 2 (FGF2) induced cell proliferation in Y1 cells. This occurs via cAMP/PKA signaling, downregulating c-Myc and dephosphorylating AKT/PKB.
Area of Science:
- Cell Biology
- Molecular Endocrinology
- Cancer Research
Background:
- Adrenocorticotropic hormone (ACTH) and fibroblast growth factor 2 (FGF2) have opposing effects on Y1 adrenocortical tumor cell proliferation.
- ACTH acts as an anti-mitogenic agent, while FGF2 is mitogenic, with FGF2's effects occurring at the G1 phase of the cell cycle.
Purpose of the Study:
- To elucidate the anti-mitogenic mechanisms of ACTH in Y1 cells, specifically how it counteracts FGF2-induced proliferation.
- To investigate the roles of c-Myc and AKT/PKB signaling pathways in ACTH's anti-mitogenic effects.
Main Methods:
- Y1 adrenocortical tumor cells were used, some with PKA deficiency.
- Experiments involved cell cycle arrest, mitogen stimulation (ACTH and FGF2), protein analysis (c-Myc, AKT/PKB), and gene manipulation (MycER chimera).
- Specific inhibitors (PD98059, Wortmannin) and signaling pathway activators (Ras x GTP) were employed.
Main Results:
- ACTH, mediated by cAMP/PKA, downregulates c-Myc post-transcriptionally and dephosphorylates AKT/PKB, counteracting FGF2's pro-mitogenic signaling.
- FGF2 stabilizes c-Myc via ERK-MAPK and upregulates AKT/PKB through PI3K, while ACTH inhibits these effects.
- Restoration of c-Myc levels via MycER chimera reversed ACTH's anti-mitogenic effect on DNA synthesis.
Conclusions:
- ACTH employs dual anti-mitogenic mechanisms involving c-Myc downregulation and AKT/PKB dephosphorylation, both initiated via ACTH receptors and cAMP/PKA.
- The Mad/Max/Myc transcription factor network's activity is sensitive to c-Myc levels in Y1 cells.
- Targeting these pathways could offer strategies for controlling adrenocortical tumor cell proliferation.
Related Concept Videos
Mitogens and the Cell Cycle
Amplifying Signals via Enzymatic Cascade
TGF - β Signaling Pathway

